Gene · 28402
Papers3,091
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
441 to 460 of 3,091
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75. | Cell Rep | 2023 | 36586406 | PubTator, text mining | PubMed |
| Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY. | Leukemia | 2023 | 36566271 | PubTator, text mining | PubMed |
| Clinical and molecular features of familial chronic lymphocytic leukemia: a pilot monocentric study. | Haematologica | 2023 | 36546426 | PubTator, text mining | PubMed |
| Systematic Literature Review of Real-World Effectiveness Results Data for First-Line Ibrutinib in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma. | Drugs Real World Outcomes | 2023 | 36534239 | PubTator, text mining | PubMed |
| Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selection. | Leuk Lymphoma | 2023 | 36503412 | PubTator, text mining | PubMed |
| The dynamic functions of IRF4 in B cell malignancies. | Clin Exp Med | 2023 | 36495369 | PubTator, text mining | PubMed |
Front-line fludarabine-cyclophosphamide-rituximab (FCR) in 110 patients with chronic lymphocytic leukaemia (CLL): real-life experience with long-term outcomes, toxicities and responses to second-line therapies. | Int J Hematol | 2023 | 36449134 | PubTator, text mining | PubMed |
| International Consensus Classification of acute lymphoblastic leukemia/lymphoma. | Virchows Arch | 2023 | 36422706 | PubTator, text mining | PubMed |
| Prognostic correlation of NOTCH1 and SF3B1 mutations with chromosomal abnormalities in chronic lymphocytic leukemia patients. | Cancer Rep (Hoboken) | 2023 | 36411516 | PubTator, text mining | PubMed |
| Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial. | J Clin Oncol | 2023 | 36395435 | PubTator, text mining | PubMed |
| Immunotherapy combinations for chronic lymphocytic leukemia: advantages and disadvantages. | Expert Opin Biol Ther | 2023 | 36374125 | PubTator, text mining | PubMed |
| Cardiac toxicity in a pilot study of duvelisib and ibrutinib combination therapy for chronic lymphocytic leukaemia. | Br J Haematol | 2023 | 36366824 | PubTator, text mining | PubMed |
| Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses. | Cell Host Microbe | 2023 | 36347257 | PubTator, text mining | PubMed |
| Human type I IFN deficiency does not impair B cell response to SARS-CoV-2 mRNA vaccination. | J Exp Med | 2023 | 36342455 | PubTator, text mining | PubMed |
| A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab as a First-Line Therapy in Chronic Lymphocytic Leukemia in Canada. | Pharmacoecon Open | 2023 | 36334238 | PubTator, text mining | PubMed |
| Distinct p53 phosphorylation patterns in chronic lymphocytic leukemia patients are reflected in the activation of circumjacent pathways upon DNA damage. | Mol Oncol | 2023 | 36334078 | PubTator, text mining | PubMed |
| A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL. | Blood Adv | 2023 | 36287248 | PubTator, text mining | PubMed |
| Flow cytometry as a fast, cost-effective tool to assess IGHV mutational status in CLL. | Blood Adv | 2023 | 36287221 | PubTator, text mining | PubMed |
| HDAC1 regulates the chromatin landscape to control transcriptional dependencies in chronic lymphocytic leukemia. | Blood Adv | 2023 | 36287107 | PubTator, text mining | PubMed |
| Real-world prognostic testing and treatment patterns in CLL/SLL: results from 1462 patients in the informCLL registry. | Blood Adv | 2023 | 36206191 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/28402/papers?page=23